Zacks Investment Research downgraded shares of Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Wednesday, Zacks.com reports.
According to Zacks, “Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company’s business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany. “
A number of other brokerages have also recently commented on FSNUY. Berenberg Bank lifted their price objective on Fresenius SE & Co. KGaA from €55.95 ($58.28) to €60.25 ($62.76) and gave the stock a buy rating in a research note on Wednesday, February 16th. Deutsche Bank Aktiengesellschaft decreased their price objective on Fresenius SE & Co. KGaA from €38.00 ($39.58) to €36.00 ($37.50) and set a hold rating for the company in a research note on Friday, February 25th. Societe Generale decreased their target price on Fresenius SE & Co. KGaA from €94.00 ($97.92) to €87.00 ($90.63) and set a buy rating for the company in a research note on Friday, February 25th. JPMorgan Chase & Co. decreased their target price on Fresenius SE & Co. KGaA from €34.50 ($35.94) to €33.30 ($34.69) and set a neutral rating for the company in a research note on Friday, May 13th. Finally, HSBC lowered Fresenius SE & Co. KGaA from a buy rating to a hold rating in a report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Fresenius SE & Co. KGaA currently has an average rating of Hold and a consensus target price of $44.65.
Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Rating) last issued its quarterly earnings data on Tuesday, February 22nd. The company reported $0.27 earnings per share (EPS) for the quarter. The firm had revenue of $11.40 billion during the quarter. Fresenius SE & Co. KGaA had a return on equity of 6.73% and a net margin of 4.85%. As a group, research analysts predict that Fresenius SE & Co. KGaA will post 0.91 EPS for the current fiscal year.
Fresenius SE & Co. KGaA Company Profile (Get Rating)
Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
- Get a free copy of the StockNews.com research report on Fresenius SE & Co. KGaA (FSNUY)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.